Literature DB >> 9606995

Substance P diminishes lipopolysaccharide and interferon-gamma-induced TGF-beta 1 production by cultured murine macrophages.

I Marriott1, K L Bost.   

Abstract

Recent evidence has demonstrated the importance of substance P and its receptor in macrophage-mediated inflammatory responses. While previous studies have shown that substance P can augment proinflammatory monokine production, little is known about the effects of this neuropeptide on the production of monokines that might limit inflammation. In the present study we have investigated the effect of substance P treatment on the production of transforming growth factor-beta 1 (TGF-beta 1) in cultured murine macrophages. We report that, while substance P agonist alone elicited increases in TGF-beta 1 mRNA expression and modest increases in TGF-beta 1 secretion, substance P dramatically diminished LPS- or IFN-gamma-induced TGF-beta 1 production. These results suggest a previously unrecognized mechanism where substance P may act as a proinflammatory mediator by limiting the production of excessive levels of TGF-beta 1 by LPS- or IFN-gamma-activated macrophages.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9606995     DOI: 10.1006/cimm.1998.1248

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  13 in total

1.  Neurogenic exacerbation of microglial and astrocyte responses to Neisseria meningitidis and Borrelia burgdorferi.

Authors:  Vinita S Chauhan; David G Sterka; David L Gray; Kenneth L Bost; Ian Marriott
Journal:  J Immunol       Date:  2008-06-15       Impact factor: 5.422

Review 2.  Inflammatory and immune pathways in the pathogenesis of periodontal disease.

Authors:  Ali Cekici; Alpdogan Kantarci; Hatice Hasturk; Thomas E Van Dyke
Journal:  Periodontol 2000       Date:  2014-02       Impact factor: 7.589

3.  Prophylactic and therapeutic targeting of the neurokinin-1 receptor limits neuroinflammation in a murine model of pneumococcal meningitis.

Authors:  Vinita S Chauhan; John M Kluttz; Kenneth L Bost; Ian Marriott
Journal:  J Immunol       Date:  2011-05-11       Impact factor: 5.422

4.  Substance P increases CCN2 dependent on TGF-beta yet Collagen Type I via TGF-beta1 dependent and independent pathways in tenocytes.

Authors:  Nagat Frara; Paul W Fisher; Yingjie Zhao; Joseph T Tarr; Mamta Amin; Steven N Popoff; Mary F Barbe
Journal:  Connect Tissue Res       Date:  2017-04-12       Impact factor: 3.417

Review 5.  The pathophysiology of brain swelling associated with subdural hemorrhage: the role of the trigeminovascular system.

Authors:  Waney Squier; Julie Mack; Alex Green; Tipu Aziz
Journal:  Childs Nerv Syst       Date:  2012-08-11       Impact factor: 1.475

6.  Estrogen replacement therapy prevents airway dysfunction in a murine model of allergen-induced asthma.

Authors:  Christiana Dimitropoulou; Fotios Drakopanagiotakis; Anuran Chatterjee; Connie Snead; John D Catravas
Journal:  Lung       Date:  2008-12-13       Impact factor: 2.584

7.  Murine gammaherpesvirus-68 elicits robust levels of interleukin-12 p40, but not interleukin-12 p70 production, by murine microglia and astrocytes.

Authors:  Amy Rasley; Kenneth L Bost; Ian Marriott
Journal:  J Neurovirol       Date:  2004-06       Impact factor: 2.643

8.  Osteoblasts express the inflammatory cytokine interleukin-6 in a murine model of Staphylococcus aureus osteomyelitis and infected human bone tissue.

Authors:  Ian Marriott; David L Gray; Susanne L Tranguch; Vance G Fowler; Martin Stryjewski; L Scott Levin; Michael C Hudson; Kenneth L Bost
Journal:  Am J Pathol       Date:  2004-04       Impact factor: 4.307

9.  Oral inflammatory diseases and systemic inflammation: role of the macrophage.

Authors:  Hatice Hasturk; Alpdogan Kantarci; Thomas E Van Dyke
Journal:  Front Immunol       Date:  2012-05-16       Impact factor: 7.561

10.  The Role of Th17 in Neuroimmune Disorders: Target for CAM Therapy. Part II.

Authors:  Aristo Vojdani; Jama Lambert
Journal:  Evid Based Complement Alternat Med       Date:  2011-06-16       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.